← Back to Search

Caspase Inhibitor

Emricasan (5 mg) for Cirrhosis (ENCORE-LF Trial)

Phase 2
Waitlist Available
Research Sponsored by Conatus Pharmaceuticals Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline - final treatment visit (at least 48 weeks to a max of 120 weeks)
Awards & highlights

ENCORE-LF Trial Summary

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

Eligible Conditions
  • Cirrhosis

ENCORE-LF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline - final treatment visit (at least 48 weeks to a max of 120 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline - final treatment visit (at least 48 weeks to a max of 120 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Comparison of the effect of emricasan on improving event-free survival relative to placebo, based on a composite clinical endpoint
Secondary outcome measures
Decrease in all-cause and liver specific mortality
Decrease in liver transplantation rates
Decrease in new decompensation events
+5 more

ENCORE-LF Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Emricasan (5 mg)Active Control1 Intervention
Emricasan 5mg
Group II: Emricasan (25 mg)Active Control1 Intervention
Emricasan 25 mg
Group III: PlaceboPlacebo Group1 Intervention
Matching placebo

Find a Location

Who is running the clinical trial?

Conatus Pharmaceuticals Inc.Lead Sponsor
18 Previous Clinical Trials
1,567 Total Patients Enrolled
Jean L Chan, MDStudy DirectorConatus Pharmaceuticals
1 Previous Clinical Trials
318 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis
2017. "Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03205345.
All > Nash > Cirrhosis
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top